We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Absology

ABSOLOGY is a medical equipment manufacturer that develops and mass-produces in vitro diagnostic medical devices. ABS... read more Featured Products: More products

Download Mobile App





Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: The ABSOL POCT immunoassay system is on display at MEDICA 2022 (Photo courtesy of Absology)
Image: The ABSOL POCT immunoassay system is on display at MEDICA 2022 (Photo courtesy of Absology)

Absology Co., Ltd. (Gyeonggi-do, Korea) is participating in MEDICA 2022 where the company is exhibiting its POC FIA (Fluorescence Immunoassay) analyzer that uses microfluidic technology for the accurate quantitative diagnosis of concentration of biomarkers for a range of diseases.

At MEDICA 2022, Absology is showcasing its ABSOL POCT analyzer that uses FIA technology to quantitatively diagnose the concentration of biomarkers. It has a test time of only five minutes and features a vivid expressed GUI along with a convenient built-in printer. Alongside ABSOL, the company is showcasing the ABSOL HS high-sensitive ELISA analyzer for early disease screening. ABSOL HS can detect Femtogram level molecules using Absology’s proprietary PIFA (Photooxidation Induced Fluorescence Amplification) technology. It has a test time of only 30 minutes and requires just 20uL of blood sample. Compact and affordable, the portable and light weight ABSOL HS is a flexible platform for any kind of ELISA protocol. Absology offers a wide test menu for the ABSOL and ABSOL HS systems, including PSA, Testosterone, Vitamin D, TSH, FreeT4, Thyroid Combo, Cortisol, PCT, COVID-19 IgM/IgG, COVID-19 Ag, COVID-19 Neutralizing Antibody, and Influenza A/B.

Related Links:
Absology Co., Ltd. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.